Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) are currently the two FDA approved CAR T-cell products targeting B-cell maturation antigen (BCMA) for the treatment of R/R Multiple Myeloma (MM) [11, 12]. Here, TNFRSF17 is linked to plasma cell myeloma.